Active material: Etifoxine
When ATH: N05BX03
CCF: Tranquillizer (anxiolytic)
ICD-10 codes (testimony): F40, F48.0
Manufacturer: BIOCODEX (France)
Capsules gelatin, smooth, bright, №2, with a white body and a blue cap; содержимое капсул – порошок белого или белого со слабым желтоватым оттенком цвета.
| 1 caps. | |
| etifoxine | 50 mg |
Excipients: lactose monohydrate, talc, microcrystalline cellulose, Colloidal anhydrous silica, magnesium stearate.
The composition of the shell: Titanium dioxide, gelatin, indigokarmin.
12 PC. – блистеры (2) – пачки картонные.
20 PC. – блистеры (3) – пачки картонные.
Anxiolytic (tranquillizer). Benzoxazine derivative, It has anxiolytic activity, less sedative effect.
Selectively affects the chlorinated channels supramolekuljarnogo GABA-benzodiazepine-chloro-ионофор receptor complex, by stimulating GABA-ergicheskuju transfer. Не вызывает привыкания и синдрома “отмены”.
Absorption
After oral administration, the drug is rapidly absorbed from the gastrointestinal tract. The time to reach Cmax in the blood is 2-3 no.
Distribution
It penetrates through the placental barrier.
Metabolism
Rapidly metabolized in the liver prior to the formation of several metabolites. Один из метаболитов – диэтилэтифоксин – является активным.
Deduction
Write mainly with urine in the form of metabolites, as well as in small quantities in an unmodified form. T1/2 each ampoule contains etiphocsine is about 6 no, T1/2 активного метаболита – 20 no.
— eliminate anxiety, fear, internal stress, increased irritability, reduce mood (incl. against the background of systemic diseases, particularly cardiovascular nature).
The drug is taken orally by 1 capsule 3 times / day, or 2 capsules 2 times / day, with a little water. The course of treatment usually lasts from a few days to 4-6 weeks.
Dose and duration of treatment should be determined individually, depending on the condition of the patient.
CNS: slight drowsiness, appearing in the early days of admission and typically disappearing yourself during treatment.
Allergic reactions: редко – кожные высыпания, hives, angioedema.
- State of shock;
- Myasthenia;
- Severe liver;
- Severe renal dysfunction;
- Childhood and adolescence up 18 years;
- Hypersensitivity to the drug.
Use of the drug during pregnancy and lactation is contraindicated.
Upon detection of pregnancy during treatment with Strezam®, should consult with a physician about continued treatment.
Consisting of Strezama® lactose is present, that should be taken into account when appointing drug patients with galaktozemiej, malabsorption syndrome, glucose and galactose, as well as in the case of lactase deficiency.
In case of skipping the dose should not double the dose the next admission.
The doctor prescribed dose should not exceed.
It is not recommended to take the drug while drinking alcoholic beverages.
Use in Pediatrics
It is not recommended to use the drug in children and adolescents under the age of 18 years.
Effects on ability to drive vehicles and management mechanisms
In connection with the risk of drowsiness should avoid vehicles and control activities, requiring greater attention, eg, control various mechanisms.
Symptoms: slackness, hypersomnia.
Treatment: gastric lavage with plenty of water, symptomatic treatment. The specific antidote is absent.
Strezam® potenziruet effect preparations, CNS depressants (incl. Opioid analgesics, ʙarʙituratov, sleeping pills, antihistamines, neuroleptics).
Strezam® increases the impact of ethanol.
The drug is released under the prescription.
The drug should be stored out of reach of children at temperature from 15 ° to 25 ° C. Shelf life - 3 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More